Hepatitis B virus cure: targets and future therapies HW Lee, JS Lee, SH Ahn International journal of molecular sciences 22 (1), 213, 2020 | 102 | 2020 |
Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease Y Kim, E Han, JS Lee, HW Lee, BK Kim, MK Kim, HS Kim, JY Park, ... Gut and liver 16 (2), 290, 2022 | 59 | 2022 |
Risk stratification using sarcopenia status among subjects with metabolic dysfunction‐associated fatty liver disease HS Chun, MN Kim, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, ... Journal of cachexia, sarcopenia and muscle 12 (5), 1168-1178, 2021 | 39 | 2021 |
A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea JS Lee, BK Kim, SU Kim, JY Park, SH Ahn, JS Seong, KH Han Clinical and Molecular Hepatology 26 (1), 24, 2020 | 38 | 2020 |
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B MY Jeon, BK Kim, JS Lee, HW Lee, JY Park, SH Ahn, KH Han, SU Kim Clinical and Molecular Hepatology 27 (2), 295, 2021 | 34 | 2021 |
The modified Response Evaluation Criteria in Solid Tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial … JS Lee, HJ Choi, BK Kim, JY Park, SH Ahn, KH Han, SE Baek, YE Chung, ... Gut and liver 14 (6), 765, 2020 | 27 | 2020 |
Empirical treatment with carbapenem vs third-generation cephalosporin for treatment of spontaneous bacterial peritonitis SW Kim, JS Yoon, J Park, YJ Jung, JS Lee, J Song, HA Lee, YS Seo, ... Clinical Gastroenterology and Hepatology 19 (5), 976-986. e5, 2021 | 24 | 2021 |
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B HW Lee, YY Cho, H Lee, JS Lee, SU Kim, JY Park, DY Kim, SH Ahn, ... Journal of Viral Hepatitis 28 (11), 1570-1578, 2021 | 21 | 2021 |
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B HW Lee, YY Cho, H Lee, JS Lee, SU Kim, JY Park, DY Kim, SH Ahn, ... Hepatology International 15 (5), 1083-1092, 2021 | 21 | 2021 |
Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes HS Chun, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, YH Lee, ... Journal of Gastroenterology and Hepatology 36 (6), 1703-1713, 2021 | 19 | 2021 |
Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease E Han, Y Lee, JS Lee, HW Lee, BK Kim, JY Park, SH Ahn, BW Lee, ... Gut and liver 16 (5), 786, 2022 | 17 | 2022 |
Liver stiffness-based risk prediction model for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease JS Lee, DH Sinn, SY Park, HJ Shin, HW Lee, BK Kim, JY Park, DY Kim, ... Cancers 13 (18), 4567, 2021 | 15 | 2021 |
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years HW Lee, JS Lee, BK Kim, JY Park, SH Ahn, SU Kim Journal of Diabetes and its Complications 35 (1), 107747, 2021 | 15 | 2021 |
An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate TS Lim, JS Lee, BK Kim, HW Lee, MY Jeon, SU Kim, JY Park, DY Kim, ... Journal of Viral Hepatitis 27 (3), 316-322, 2020 | 15 | 2020 |
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease HS Chun, M Lee, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, ... Liver International 43 (3), 608-625, 2023 | 13 | 2023 |
Predictive performance of CAGE-B and SAGE-B models in Asian treatment-naive patients who started entecavir for chronic hepatitis B HY Chon, JS Lee, HW Lee, HS Chun, BK Kim, WY Tak, JY Park, ... Clinical Gastroenterology and Hepatology 20 (4), e794-e807, 2022 | 13 | 2022 |
Comparison of FibroScan-aspartate aminotransferase (FAST) score and other non-invasive surrogates in predicting high-risk non-alcoholic steatohepatitis criteria JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, JY Jang, SY Park, ... Frontiers in Medicine 9, 869190, 2022 | 12 | 2022 |
Episodic detectable viremia does not affect prognosis in untreated compensated cirrhosis with serum hepatitis B virus DNA< 2,000 IU/mL HW Lee, SY Park, YR Lee, H Lee, JS Lee, SU Kim, JY Park, SH Ahn, ... Official journal of the American College of Gastroenterology| ACG 117 (2 …, 2022 | 12 | 2022 |
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir JW Chang, JS Lee, HW Lee, BK Kim, JY Park, DY Kim, SH Ahn, YS Seo, ... Journal of Viral Hepatitis 28 (1), 95-104, 2021 | 12 | 2021 |
Hepatocellular carcinoma risk according to regimens for eradication of hepatitis C virus; interferon or direct acting antivirals HW Lee, DH Han, HJ Shin, JS Lee, SU Kim, JY Park, DY Kim, SH Ahn, ... Cancers 12 (11), 3414, 2020 | 12 | 2020 |